919 related articles for article (PubMed ID: 24654427)
1. Treatment guidelines for latent tuberculosis infection.
;
Kekkaku; 2014 Jan; 89(1):21-37. PubMed ID: 24654427
[TBL] [Abstract][Full Text] [Related]
2. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
5. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M
Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286
[TBL] [Abstract][Full Text] [Related]
6. [Reconsideration of the admission and discharge criteria of tuberculosis patients in Japan].
Masuyama H; Igari H
Kekkaku; 2013 Mar; 88(3):373-85. PubMed ID: 23672177
[TBL] [Abstract][Full Text] [Related]
7. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
[TBL] [Abstract][Full Text] [Related]
9. Advances in diagnosis and treatment of latent tuberculosis infection.
Chapman HJ; Lauzardo M
J Am Board Fam Med; 2014; 27(5):704-12. PubMed ID: 25201941
[TBL] [Abstract][Full Text] [Related]
10. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
Sato S; Nagai H
Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
[TBL] [Abstract][Full Text] [Related]
11. Missed opportunities for tuberculosis prevention among patients accessing a UK HIV service.
Rickman HM; Miller RF; Morris-Jones S; Kellgren L; Edwards SG; Grant AD
Int J STD AIDS; 2018 Oct; 29(12):1234-1237. PubMed ID: 29749875
[TBL] [Abstract][Full Text] [Related]
12. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
[TBL] [Abstract][Full Text] [Related]
13. [Patient-centered medicine for tuberculosis medical services].
Fujita A; Narita T
Kekkaku; 2012 Dec; 87(12):795-808. PubMed ID: 23350521
[TBL] [Abstract][Full Text] [Related]
14. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
17. Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period.
Sidhu A; Verma G; Humar A; Kumar D
Transplantation; 2014 Sep; 98(6):671-5. PubMed ID: 24825525
[TBL] [Abstract][Full Text] [Related]
18. [Compliance with latent tuberculosis treatment: a public health challenge].
Bishara H; Ore L; Ravell DW
Harefuah; 2014; 153(3-4):167-70, 239, 238. PubMed ID: 24791558
[TBL] [Abstract][Full Text] [Related]
19. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
[TBL] [Abstract][Full Text] [Related]
20. Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence.
Vidal JS; Silva MT; Sanchez MN
Rev Soc Bras Med Trop; 2015; 48(5):507-13. PubMed ID: 26516958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
